Aakash Desai: The biomarker landscape of ADCs and bispecific antibodies (BsAbs) in Lung cancer

Aakash Desai, Assistant Professor at O’Neal Comprehensive Cancer Center at UAB, shared on LinkedIn:

“Excited to share the findings from our study on the biomarker landscape of antibody-drug conjugates (ADCs) and bispecific antibodies (BsAbs) in clinical trials for Lung Cancer at WCLC24!

Biomarker Landscape in Lung Cancer Clinical Trials

Key insights:

• 47 clinical trials reviewed
• Biomarkers are crucial in ADC/BsAb trials, with 45% including biomarkers
• EGFR, MET, and TROP2 among the top biomarkers identified !”

Source: Aakash Desai/LinkedIn